Recently, Shen et al. reported that plasma GFAP is significantly elevated from the preclinical stage of AD and is a promising diagnostic and predictive biomarker that distinguishes AD from the controls and non-AD dementia [43]. This evidence concerns the gene GFAP and dementia.